Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Condition(s):Breast NeoplasmsLast Updated:August 8, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Breast NeoplasmsLast Updated:August 8, 2023Recruiting
Condition(s):Breast NeoplasmsLast Updated:November 8, 2023Recruiting
Condition(s):Breast NeoplasmsLast Updated:August 8, 2023Recruiting
Condition(s):Breast CancerLast Updated:December 14, 2023Recruiting
Condition(s):HER2-negative Breast CancerLast Updated:June 5, 2023Recruiting
Condition(s):Breast CancerLast Updated:February 20, 2024Recruiting
Condition(s):Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast CarcinomaLast Updated:March 19, 2024Not yet recruiting
Condition(s):Breast CancerLast Updated:March 6, 2024Recruiting
Condition(s):Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast CancerLast Updated:March 23, 2023Recruiting
Condition(s):Metastatic HER2 Negative Breast Carcinoma; Brain Metastases; Capecitabine; UDT1Last Updated:September 10, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.